Biophytis S.A. (ALBPS.PA) reports earnings on 28 Feb 2026 while trading pre-market at €0.057 on EURONEXT. This ALBPS.PA stock update focuses on the earnings event as a potential catalyst for short-term volatility. Investors will watch cash runway, trial progress for Sarconeos (BIO101) and guidance for 2026. Volume ahead of the release is elevated at 1,318,853 shares, so price moves may magnify. We examine fundamentals, technicals, and a model forecast to isolate the key outcomes investors should expect.

Earnings timing and what matters for ALBPS.PA stock

Biophytis files results tied to clinical and cash updates on 28 Feb 2026. The market will parse progress on Sarconeos (BIO101) and any commentary about Phase 2/3 programs. Management commentary on financing plans and milestones will influence the ALBPS.PA stock reaction.

One clear metric to watch is cash per share, reported at €0.0627 TTM, and any guidance on runway. For a clinical-stage biotech with no commercial revenue, cash and trial readouts drive near-term moves.

Price, liquidity and fundamentals driving ALBPS.PA stock

ALBPS.PA trades at €0.057 with a market cap of €1,210,323.00 and daily volume 1,318,853. The 50-day average price is €0.06155 and the 200-day average is €0.11792. EPS is -0.34 and reported PE is -0.15, reflecting negative earnings.

Technical ranges show a year high of €0.404 and a year low of €0.0512. Shares outstanding are 23,230,769, which matters when management discusses potential capital raises and dilution.

Meyka AI grade and technical snapshot for ALBPS.PA stock

Meyka AI rates ALBPS.PA with a score out of 100: 71.18 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Technicals show RSI 47.78, ADX 29.36, and Bollinger band mid €0.060. Momentum is muted and the stock sits below its 200-day average, signaling a risk-on trade driven by binary news rather than trending strength.

Catalysts and risks shaping ALBPS.PA stock

Primary catalysts are clinical readouts, regulatory updates, and any financing announcements. Positive Phase results or clear partnerships could sharply re-rate ALBPS.PA stock. The healthcare sector backdrop is mixed, and biotech flows can amplify moves.

Key risks include cash shortfall, trial setbacks, and dilution from capital raises. The company’s EV-to-EBITDA and balance metrics show stress—current ratio 0.35—so funding language in the earnings release is critical.

Analyst view, price targets and ALBPS.PA stock forecast

Market consensus data is limited and formal analyst targets are sparse. A conservative near-term price target to watch is the 200-day average at €0.118. A downside scenario sees shares test the near-year low at €0.051 if results disappoint.

Meyka AI’s forecast model projects €2.20 as a long-run figure. Versus the current €0.057, that implies an approximate upside of +3,760.00%. Forecasts are model-based projections and not guarantees.

Trading strategy ahead of the earnings release for ALBPS.PA stock

Traders should use tight risk controls because the stock is low-priced and volatile. Consider position sizing that limits loss to a set percentage per trade due to potential dilution or gap moves.

Long-term investors need to weigh pipeline value against cash runway. If management signals a clear funding path, the stock could recover toward the 50-day average. Otherwise, expect continued pressure and possible capital raise dilution.

Final Thoughts

ALBPS.PA stock faces a high-stakes earnings release on 28 Feb 2026 that will likely determine near-term direction. The company trades at €0.057, with negative EPS -0.34 and constrained liquidity metrics. The clinical pipeline, especially Sarconeos (BIO101), is the primary upside driver. Meyka AI’s forecast model projects €2.20, implying roughly +3,760.00% from today’s level, but that figure depends on successful clinical outcomes and funding. Those forecasts are model-based projections and not guarantees. Our view: treat the report as a binary catalyst. If management confirms adequate runway and positive trial signals, ALBPS.PA stock could rerate toward the 50-day average (€0.062 to €0.118). If the update flags cash stress or trial delays, downside toward the year low (€0.051) is likely. Use strict risk controls and monitor official releases on the company site and EURONEXT quote page for verified details. Meyka AI provides this as AI-powered market analysis, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.